Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer.

Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Rev Anticancer Ther. 2019 Aug 30;:1-17 Authors: Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Capitanio U, Cucchiara V, Mazzone E, Bravi CA, Mirone V, Montorsi F, Briganti A Abstract Introduction: A considerable proportion of patients are still found with nodal involvement when considering prostate (PCa), bladder (BCa) and renal cancer (RCC). This scenario is often related to poorer oncological outcomes, but evidence supporting this correlation remain scarce or controversial. Areas covered: A review was conducted to provide updated evidence in the field of pathological nodal involvement in PCa, BCa, and RCC. Nodal-staging process, role of lymphadenectomy and available therapeutic strategies were covered. Expert opinion: Nodal staging mostly relies on CT scan. FDG-PET for BCa and RCC and PSMA-PET for PCa have shown promising results, although some issues like availability and cost-effectiveness still need to be addressed. For PCa, pre-operative nomograms have almost completely replaced the need for imaging with nodal staging purposes. Still, the gold standard remains lymphadenectomy. The oncological benefit of LND is still not clear for PCa and RCC but is related to a better oncological outcome for BCa. For PCa the use of androgen deprivation therapy combined with radiotherapy, particularly in men with high risk of local recu...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research

Related Links:

ConclusionsCoverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant compared with ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogues between ASTRO members, payers, and policymakers remain essential.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
AbstractWe prospectively validate the efficacy of the frailty discriminant score (FDS) in individuals with urological cancers, as there has been growing importance in evaluating frailty in clinical practice. A prospective, multicenter study was conducted from February 2017 to April 2019. We enrolled 258 patients with urological cancers and 301 community-dwelling participants who were assessed for frailty. Frailty was assessed using FDS that includes ten items, such as physical, mental, and blood biochemical tests. The primary outcome was the non-inferiority (margin 5%) of FDS in discriminating patients with urological canc...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Immunotherapy is a key treatment in kidney and bladder cancer. In the future, the identification of predictive markers should allow us to better select patients responding to immunotherapy. PMID: 31477432 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
The treatment of genitourinary malignancies has dramatically evolved over recent years. Renal cell carcinoma, urothelial carcinoma of the bladder, and prostate adenocarcinoma are the most commonly encountered ...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research
CONCLUSIONSCoverage guidelines for IMRT, SRS, SABR, and PBT vary across 5 major insurance providers and may be substantially discordant when compared to ASTRO coverage guidelines. There remain several specific areas where ongoing and future dialogue between ASTRO, payers, and policymakers remains essential.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Hematuria is prevalent in up to a third of the US population. Approximately 2% to 5% of patients with microscopic hematuria and 12% of patients with macroscopic or gross hematuria will be diagnosed with urinary tract cancer, most cases of which are superficial bladder tumors detected through cystoscopy. Screening asymptomatic persons for bladder cancer with urinalysis to detect microscopic hematuria is not recommended by the US Preventive Services Task Force because of insufficient evidence of the advantage of treatment of screen-detected bladder cancer, as well as insufficient data on the harms of screening for and evalua...
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
Lynch Syndrome (LS) entails a defective DNA mismatch repair system, which is the post-replicative proofreading and editing system, ensuring our genome's integrity. LS predisposes to several cancers, most commonly colorectal and endometrial cancers. LS occurs in approximately 1 in 250 –1,000 people.LS is associated with urological malignancies with upper tract urothelial carcinoma the most common, although still clinically underestimated. Other urologic malignancies possibly associated with LS include bladder, prostate, testis, and renal cell carcinoma.
Source: Urology - Category: Urology & Nephrology Authors: Source Type: research
Conclusion: In cancer patients, MIE should be monitored in those with genitourinary cancer, especially with renal dysfunction. Longer duration with more cumulative dose also has a greater risk of MIE. Early consideration of MIE with prompt cessation of metronidazole may result in better outcome.
Source: Annals of Indian Academy of Neurology - Category: Neurology Authors: Source Type: research
This review focuses on what is the biological basis of esophageal cancer for immunotherapy, how to screen out the patients who can benefit from immunotherapy, and whether the toxic side effects of immunotherapy are manageable. AbstractConsidering the benefits of immunotherapy in advanced melanoma, non –small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the applicatio n of immunotherapy suc...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Kidney Cancer | PET Scan | Urology & Nephrology